Lisata Therapeutics, Inc. (LSTA) is a Biotechnology company in the Healthcare sector, currently trading at $4.01. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Valuation: LSTA trades at a trailing Price-to-Earnings (P/E) of -2.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.08.
Financials: revenue is $170,000, -91.5%/yr average growth. Net income is $17M (loss), growing at +27.6%/yr. Net profit margin is -9756.5% (negative). Gross margin is 14.1% (-38.4 pp trend).
Balance sheet: total debt is $0 against $15M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 5.76 (strong liquidity). Debt-to-assets is 0%. Total assets: $18M.
Analyst outlook: 1 / 2 analysts rate LSTA as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 7/100 (Fail), Future 40/100 (Partial), Income 10/100 (Fail).
